Virion Therapeutics Reports Phase 1b Data for HBV Immunotherapy VRON-0200
PHILADELPHIA, PA — Virion Therapeutics LLC reported data showing its experimental hepatitis B immunotherapy VRON-0200 generated sustained immune responses in chronically infected patients following a single dose, the company announced …
Virion Therapeutics Reports Phase 1b Data for HBV Immunotherapy VRON-0200 Read More